During the corresponding time, Pharming Group N V recorded a revenue increase by 26.56 % year on year, While revenue at the Pharming Group N V 's corporate clients
Pharming Group N V's Comment on Sales, Marketing and Customers
The company operates in the market for treatments of Hereditary Angioedema (HAE), focusing on its product RUCONEST®. Its customer base includes physicians, patients, payors, and other stakeholders within the acute HAE market. RUCONEST® competes with several approved products in the U.S. and Europe, including human blood plasma-derived C1-inhibitor (C1INH) products and EKTERLY® (sebetralstat), an oral treatment approved in the U.S. in 2025. The HAE market is also advancing with the development of additional oral therapies and potential gene therapies. Competitors include major international pharmaceutical companies, smaller or regional specialty pharmaceutical and biotechnology firms, and early-stage companies, some of which collaborate with larger established companies. Key factors influencing competition are safety, efficacy, tolerability, reliability, dosing convenience, price, and reimbursement. RUCONEST® is not approved for prophylactic use, and new prophylactic therapies approved by the FDA in 2025 may decrease the demand for acute rescue treatments such as RUCONEST®.
Pharming Group N V’s Comment on Sales, Marketing and Customers
The company operates in the market for treatments of Hereditary Angioedema (HAE), focusing on its product RUCONEST®. Its customer base includes physicians, patients, payors, and other stakeholders within the acute HAE market. RUCONEST® competes with several approved products in the U.S. and Europe, including human blood plasma-derived C1-inhibitor (C1INH) products and EKTERLY® (sebetralstat), an oral treatment approved in the U.S. in 2025. The HAE market is also advancing with the development of additional oral therapies and potential gene therapies. Competitors include major international pharmaceutical companies, smaller or regional specialty pharmaceutical and biotechnology firms, and early-stage companies, some of which collaborate with larger established companies. Key factors influencing competition are safety, efficacy, tolerability, reliability, dosing convenience, price, and reimbursement. RUCONEST® is not approved for prophylactic use, and new prophylactic therapies approved by the FDA in 2025 may decrease the demand for acute rescue treatments such as RUCONEST®.
Sources:
Pharming Group N v’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Pharming Group N v’s corporate clients.
For your research, we’ve provided 9 tables on Pharming Group N v corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
84.64 %